| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5692245 | European Urology | 2017 | 9 Pages |
Abstract
We analyzed outcomes for patients with metastatic castration-resistant prostate cancer on androgen receptor signaling inhibitors and standard chemotherapy. Patients with circulating tumor cells that had AR-V7 protein in the cellular nuclei were very likely to survive longer on taxane-based chemotherapy, and tests unable to distinguish where the protein is located in the cell are not as predictive of benefit.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Howard I. Scher, Ryon P. Graf, Nicole A. Schreiber, Brigit McLaughlin, David Lu, Jessica Louw, Daniel C. Danila, Lyndsey Dugan, Ann Johnson, Glenn Heller, Martin Fleisher, Ryan Dittamore,